PBE
Invesco Biotechnology & Genome ETF
$95.95+0.26 (+0.27%)Close Nov 18, 2026
Adjusted price
+24.80% total return, past year
Key statistics
- Expense ratio
- 0.59%
- Dividend yield
- 1.39%
- 52-week range
- $75.60$104.67
- All-time high close
- $104.67 on Nov 4, 2026
- From all-time high
- −8.33%
- Max drawdown
- −45.69%
- Volatility
- 25.22%
- Sharpe ratio
- 0.48
- Beta (5Y monthly)
- 0.71
Returns
Total
- 1M
- −0.14%
- YTD
- +18.08%
- 1Y
- +24.80%
Per year
- 3Y
- +20.36%
- 5Y
- +6.06%
- 10Y
- +8.68%
- 20Y
- +8.71%
- Since 2005
- +9.43%
Fund facts
As of Jul 31, 2026- Net assets
- $282M
- Holdings
- 33
- Top 10 holdings
- 56.8%
- Stocks
- 100.0%
- Cash
- 17.9%
Sectors
- Health Care
- 100.0%
Top holdings
| Holding | Weight (%) |
|---|---|
| Invesco Private Prime Fund | 12.9 |
| REGNRegeneron Pharmaceuticals, Inc. | 5.5 |
| AMGNAmgen Inc. | 5.2 |
| CDNACareDx, Inc. | 5.0 |
| VRTXVertex Pharmaceuticals Incorporated | 5.0 |
| Invesco Private Government Fund | 5.0 |
| RPRXRoyalty Pharma plc | 4.9 |
| BIIBBiogen Inc. | 4.8 |
| GILDGilead Sciences, Inc. | 4.4 |
| UTHRUnited Therapeutics Corporation | 4.1 |